azacitidine has been researched along with losartan potassium in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (5.13) | 18.7374 |
| 1990's | 6 (15.38) | 18.2507 |
| 2000's | 14 (35.90) | 29.6817 |
| 2010's | 15 (38.46) | 24.3611 |
| 2020's | 2 (5.13) | 2.80 |
| Authors | Studies |
|---|---|
| Nienhuis, AW; Stamatoyannopoulos, JA | 1 |
| Constantoulakis, P; Costantini, F; Enver, T; Josephson, B; Mangahas, L; Papayannopoulou, T; Stamatoyannopoulos, G | 1 |
| Charache, S | 1 |
| DeSimone, J; Eves, EM; Heller, P | 1 |
| Charache, S; Dover, GJ | 1 |
| DeSimone, J; Heller, P; Lavelle, D | 1 |
| Olivieri, NF | 1 |
| Pearson, HA | 1 |
| Li, J; Noguchi, CT; Schechter, AN; Smith, RD | 1 |
| Rodgers, GP; Saunthararajah, Y | 1 |
| Gabrilove, JL | 1 |
| Baiocchi, M; Di Baldassarre, A; Di Pietro, R; Di Rico, C; Migliaccio, AR | 1 |
| Sumida, KN; Suwanawiboon, B | 1 |
| Odenike, O; Tefferi, A | 1 |
| Nimer, SD | 1 |
| Thomas, ML | 1 |
| Steensma, DP; Tefferi, A | 1 |
| Cosler, LE; Ferro, SA; Greenberg, PL; Lyman, GH | 1 |
| Stone, RM | 1 |
| Becherer, K; Caldwell, C; Diaz-Arias, A; Feldman, M; Golda, N | 1 |
| Ishikawa, T | 1 |
| Lachs, MS; Ritchie, EK | 1 |
| Galili, N; Raza, A | 1 |
| Fenaux, P; Garcia-Manero, G | 1 |
| Chan, EM; Chan, RJ; Cripe, LD; Hood, D; Hui, CL; Kohlbacher, KJ; Nabinger, SC; Orschell, CM; Plett, A; Sampson, C; Sayar, H; Walter, A; West, ES; Wu, J; Yang, Z; Yu, Z | 1 |
| Cornfield, DB | 1 |
| Bocchia, M; Candoni, A; Cattina, F; Clissa, C; Cocco, L; Defina, M; Fanin, R; Filì, C; Finelli, C; Follo, MY; Gobbi, M; Iacobucci, I; Malagola, M; Manzoli, L; Martinelli, G; Russo, D; Skert, C; Spedini, P | 1 |
| Guinea de Castro, JM; Moreno de Gusmão, B; Oiartzabal, I; Perez-Persona, E | 1 |
| Tohyama, K | 1 |
| Meers, S | 1 |
| Usuki, K | 1 |
| Chang, FC; Chang, YT; Chen, YM; Chiang, WC; Chou, YH; Chu, TS; Hsu, HL; Lai, CF; Lin, CH; Lin, SL; Pan, SY; Tsai, MH; Wu, MS; Yang, CC | 1 |
| Allison, SJ | 1 |
| Bastié, JN; Ben Abdelali, R; Beyne-Rauzy, O; Chaury, MP; Chermat, F; Chevret, S; Cheze, S; Choufi, B; Delaunay, J; Dreyfus, F; Fenaux, P; Gardin, C; Guerci-Bresler, A; Legros, L; Park, S; Prébet, T; Preudhomme, C; Renneville, A; Sanhes, L; Stamatoullas, A; Tertian, G; Thépot, S; Vey, N; Wattel, E | 1 |
| Santini, V | 1 |
| Behrens, YL; Göhring, G; Lentes, J; Rothe, D; Schlegelberger, B; Steinemann, D; Thomay, K; Wittig, V; Wittner, N | 1 |
| Abe, M; Arai, N; Ariizumi, H; Baba, Y; Fujiwara, S; Harada, H; Hattori, N; Kabasawa, N; Kawaguchi, Y; Murai, S; Nakamaki, T; Saito, B; Sasaki, Y; Shimada, S; Tsukamoto, H; Uto, Y; Yanagisawa, K | 1 |
| Balleari, E; Campelo, MD; Fenaux, P; Germing, U; Götze, KS; Guerci-Bresler, A; Hamel, JF; Kelaidi, C; Komrokji, R; Kotsianidis, I; Park, S; Santini, V; Sanz, GF; Sekeres, MA; Stamatoullas, A; Steensma, D; Thépot, S; Toma, A | 1 |
| Sekeres, MA; Taylor, J | 1 |
21 review(s) available for azacitidine and losartan potassium
| Article | Year |
|---|---|
Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythropoietin; Fetal Hemoglobin; Gene Expression Regulation; Hemoglobinopathies; Humans; Hydroxyurea; Thalassemia | 1992 |
Hydroxyurea as treatment for sickle cell anemia.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythropoietin; Humans; Hydroxyurea | 1991 |
Chemotherapy and hemoglobin F synthesis in sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Clinical Trials as Topic; Erythropoietin; Fetal Hemoglobin; Humans; Hydroxyurea; Interleukin-3; Papio; Recombinant Proteins | 1989 |
Fetal hemoglobin reactivation in baboon and man: a short perspective.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Butyrates; Butyric Acid; Erythropoietin; Fetal Hemoglobin; Humans; Hydroxyurea; Papio | 1993 |
Reactivation of fetal hemoglobin in patients with beta-thalassemia.
Topics: Azacitidine; beta-Thalassemia; Butyrates; Butyric Acid; Erythropoietin; Fetal Hemoglobin; Homozygote; Humans; Hydroxyurea; Treatment Outcome | 1996 |
Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality.
Topics: Anemia, Sickle Cell; Antineoplastic Agents; Antisickling Agents; Azacitidine; beta-Thalassemia; Erythropoietin; Fetal Hemoglobin; Humans; Hydroxyurea; Phenylbutyrates | 1996 |
Advances in experimental treatment of beta-thalassaemia.
Topics: Azacitidine; beta-Thalassemia; Drug Therapy, Combination; Erythropoietin; Histone Deacetylase Inhibitors; Humans; Hydroxyurea; Iron Chelating Agents | 2001 |
Hematologic malignancies: an opportunity for targeted drug therapy.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; DNA, Neoplasm; Erythropoietin; Hematologic Neoplasms; Humans; Recombinant Proteins; Thrombocytopenia | 2001 |
5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Hematopoietic Cell Growth Factors; Humans; Male; Myelodysplastic Syndromes; Thrombocytopenia | 2004 |
Conventional and new treatment options for myelofibrosis with myeloid metaplasia.
Topics: Androgens; Angiogenesis Inhibitors; Antineoplastic Agents; Azacitidine; Benzamides; Chronic Disease; Decitabine; Erythropoietin; Humans; Imatinib Mesylate; Piperazines; Primary Myelofibrosis; Pyrimidines; Quinolones; Recombinant Proteins | 2005 |
Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Topics: Anemia, Hypochromic; Azacitidine; Bone Marrow; Chromosome Aberrations; Chromosomes, Human, Pair 5; Erythrocyte Transfusion; Erythropoiesis; Erythropoietin; Gene Deletion; Hematinics; Hematopoietic Stem Cell Transplantation; Humans; Karyotyping; Lenalidomide; Myelodysplastic Syndromes; Predictive Value of Tests; Prognosis; Randomized Controlled Trials as Topic; Recombinant Proteins; Thalidomide | 2006 |
Strategies for achieving transfusion independence in myelodysplastic syndromes.
Topics: Anemia; Antilymphocyte Serum; Antimetabolites, Antineoplastic; Azacitidine; Decitabine; Drug Costs; Erythrocyte Transfusion; Erythropoietin; Health Services Needs and Demand; Humans; Immunosuppressive Agents; Informed Consent; Myelodysplastic Syndromes; Nurse's Role; Oncology Nursing; Patient Education as Topic; Patient Selection; Quality of Life; Thalidomide; Treatment Outcome | 2007 |
Risk-based management of myelodysplastic syndrome.
Topics: Anemia, Sideroblastic; Antilymphocyte Serum; Azacitidine; Benzoates; Decitabine; Deferasirox; DNA Modification Methylases; Enzyme Inhibitors; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Histone Deacetylase Inhibitors; Humans; Immunosuppressive Agents; Interleukin-11; Iron Chelating Agents; Lenalidomide; Leukemia, Myelomonocytic, Chronic; Myelodysplastic Syndromes; Prognosis; Risk; Stem Cell Transplantation; Thalidomide; Triazoles | 2007 |
How I treat patients with myelodysplastic syndromes.
Topics: Acute Disease; Aged; Azacitidine; Chelation Therapy; Chromosome Deletion; Chromosomes, Human, Pair 5; Clinical Trials as Topic; Decitabine; Disease Progression; DNA Methylation; Erythropoietin; Hematopoietic Cell Growth Factors; Hematopoietic Stem Cell Transplantation; Humans; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid; Myelodysplastic Syndromes; Severity of Illness Index; Thalidomide; Transplantation, Homologous | 2009 |
[Novel therapeutic agents for myelodysplastic syndrome].
Topics: Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Decitabine; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Humans; Lenalidomide; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Remission Induction; Thalidomide | 2009 |
Pharmacotherapy of myelodysplastic syndromes.
Topics: Azacitidine; Decitabine; DNA Methylation; Drug Approval; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; United States; United States Food and Drug Administration | 2010 |
Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
Topics: Antimetabolites, Antineoplastic; Azacitidine; Decitabine; DNA Methylation; Epoetin Alfa; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Lenalidomide; Myelodysplastic Syndromes; Prognosis; Recombinant Proteins; Thalidomide; Transplantation, Homologous | 2011 |
[Myelodysplastic syndromes: treatment strategy up-to-date].
Topics: Antilymphocyte Serum; Azacitidine; Benzoates; Cyclosporine; Cytarabine; Deferasirox; Disease Progression; Drug Discovery; Drug Therapy, Combination; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Immunosuppressive Agents; Iron Chelating Agents; Lenalidomide; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Quality of Life; Risk Assessment; Thalidomide; Triazoles | 2014 |
The myelodysplastic syndromes: the era of understanding.
Topics: Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Azacitidine; Blood Transfusion; Erythropoietin; Gene Expression Regulation, Neoplastic; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Myelodysplastic Syndromes; Neoplasm Proteins; Prognosis; Spliceosomes; Thalidomide; Transplantation, Homologous | 2015 |
[Treatment of MDS].
Topics: Allografts; Angiogenesis Inhibitors; Antimetabolites, Antineoplastic; Autografts; Azacitidine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Immunologic Factors; Immunosuppressive Agents; Induction Chemotherapy; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Recombinant Proteins; Thalidomide; Transplantation Conditioning | 2014 |
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
Topics: Antineoplastic Agents; Azacitidine; Decitabine; Erythropoietin; Female; Hematinics; Humans; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Neutropenia; Prognosis; Thrombocytopenia | 2022 |
5 trial(s) available for azacitidine and losartan potassium
| Article | Year |
|---|---|
Hydroxyurea as treatment for sickle cell anemia.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Erythropoietin; Humans; Hydroxyurea | 1991 |
Chemotherapy and hemoglobin F synthesis in sickle cell disease.
Topics: Anemia, Sickle Cell; Animals; Azacitidine; Clinical Trials as Topic; Erythropoietin; Fetal Hemoglobin; Humans; Hydroxyurea; Interleukin-3; Papio; Recombinant Proteins | 1989 |
Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.
Topics: Aged; Aged, 80 and over; Anemia; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; bcl-X Protein; Erythroid Precursor Cells; Erythropoiesis; Erythropoietin; Female; Flow Cytometry; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis | 2011 |
Prospective phase II Study on 5-days azacitidine for treatment of symptomatic and/or erythropoietin unresponsive patients with low/INT-1-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Azacitidine; Drug Administration Schedule; Erythropoietin; Female; Gene Expression Regulation, Neoplastic; Hematologic Tests; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Phospholipase C beta; Polymorphism, Single Nucleotide; Prospective Studies; Treatment Outcome; Wnt1 Protein | 2013 |
A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Biomarkers; Cytogenetic Analysis; DNA Mutational Analysis; Drug Resistance; Erythropoietin; Female; Hematinics; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Polymorphism, Single Nucleotide; Recombinant Proteins; Survival Analysis; Treatment Outcome | 2016 |
15 other study(ies) available for azacitidine and losartan potassium
| Article | Year |
|---|---|
Locus control region-A gamma transgenic mice: a new model for studying the induction of fetal hemoglobin in the adult.
Topics: Animals; Azacitidine; Base Sequence; Butyrates; Erythropoietin; Fetal Hemoglobin; Gene Expression Regulation; Genes, Regulator; Globins; Hydroxyurea; Mice; Mice, Transgenic; Molecular Sequence Data; RNA, Messenger | 1991 |
Differences in burst morphology among baboon species.
Topics: Animals; Azacitidine; Bloodletting; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Erythroblasts; Erythrocyte Count; Erythropoiesis; Erythropoietin; Fetal Hemoglobin; Hematopoietic Stem Cells; Papio; Species Specificity | 1989 |
Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells.
Topics: Adult; Azacitidine; Butyric Acid; DNA, Complementary; Erythroid Precursor Cells; Erythropoietin; Fetal Hemoglobin; Gene Expression Regulation; Globins; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Hydroxyurea; Polymerase Chain Reaction; RNA, Messenger | 2000 |
5-azacytidine reactivates the erythroid differentiation potential of the myeloid-restricted murine cell line 32D Ro.
Topics: Animals; Azacitidine; Cell Differentiation; Cell Line; Clone Cells; Erythrocytes; Erythroid Precursor Cells; Erythropoietin; Globins; Granulocyte-Macrophage Colony-Stimulating Factor; Interleukin-3; Mice; Myeloid Cells; RNA, Messenger; Transcription Factors | 2003 |
The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
Topics: Anemia; Antineoplastic Agents; Azacitidine; Cost of Illness; Costs and Cost Analysis; Darbepoetin alfa; Decision Support Techniques; Deferoxamine; Drug Costs; Drug Therapy; Epoetin Alfa; Erythropoietin; Hematinics; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Practice Guidelines as Topic; Recombinant Proteins; Siderophores; Thalidomide; United States | 2008 |
Neutrophilic panniculitis associated with myelodysplastic syndrome with abnormal nuclear forms.
Topics: Aged; Anemia; Antimetabolites, Antineoplastic; Azacitidine; Cell Nucleus Shape; Chelation Therapy; Erythropoietin; Granulocyte Colony-Stimulating Factor; Humans; Male; Myelodysplastic Syndromes; Neutrophils; Panniculitis | 2009 |
Management of myelodysplastic syndromes in the geriatric patient.
Topics: Aged; Anemia; Antineoplastic Agents; Azacitidine; Decitabine; Erythrocyte Transfusion; Erythropoietin; Humans; Iron Chelating Agents; Lenalidomide; Myelodysplastic Syndromes; Neutropenia; Thalidomide; Thrombocytopenia | 2009 |
Erythroblastic sarcoma, an extremely rare variant of myeloid sarcoma.
Topics: Abnormal Karyotype; Adenocarcinoma; Aged; Azacitidine; Biopsy, Large-Core Needle; Bone Marrow; Bone Marrow Neoplasms; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Drug Therapy, Combination; Erythroblasts; Erythropoietin; Fatal Outcome; Humans; Lymph Nodes; Male; Myelodysplastic Syndromes; Rare Diseases; Rectal Neoplasms; Sarcoma, Myeloid | 2012 |
[Transfusional independence in a patient with refractory anemia with excess blasts-2 refractory to 5-azacitidine treated with deferasirox and colony stimulating factors].
Topics: Aged; Anemia, Refractory, with Excess of Blasts; Azacitidine; Benzoates; Blood Transfusion; Chelation Therapy; Combined Modality Therapy; Deferasirox; Disease Progression; Drug Resistance; Epoetin Alfa; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Iron; Iron Chelating Agents; Leukemia, Myeloid, Acute; Male; Recombinant Proteins; Triazoles | 2014 |
DNA methyltransferase inhibition restores erythropoietin production in fibrotic murine kidneys.
Topics: Animals; Azacitidine; Basic Helix-Loop-Helix Transcription Factors; Collagen Type I; Collagen Type I, alpha 1 Chain; DNA Modification Methylases; Erythropoietin; Fibrosis; Mice; Mice, Transgenic; Myofibroblasts; Pericytes; Receptor, Platelet-Derived Growth Factor beta; Renal Insufficiency, Chronic | 2016 |
Anaemia: Targeting epigenetics in renal anaemia.
Topics: Animals; Azacitidine; DNA Modification Methylases; Erythropoietin; Myofibroblasts; Pericytes; Renal Insufficiency, Chronic | 2016 |
First-line Therapeutic Strategies for Myelodysplastic Syndromes.
Topics: Algorithms; Azacitidine; Decitabine; Enzyme Inhibitors; Erythrocyte Transfusion; Erythropoietin; Hematopoietic Stem Cell Transplantation; Humans; Myelodysplastic Syndromes; Risk Factors; Transplantation, Homologous | 2017 |
Octasomy 21 in a patient with secondary AML after CMML: the role of acquired NRAS mutations in triggering aneuploidy.
Topics: Aged; Aneuploidy; Antimetabolites, Antineoplastic; Azacitidine; Chromosomes, Human, Pair 21; Erythropoietin; Fatal Outcome; Granulocyte Colony-Stimulating Factor; GTP Phosphohydrolases; Humans; Karyotyping; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Membrane Proteins; Neoplasms, Second Primary | 2018 |
Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Erythroblasts; Erythrocyte Indices; Erythropoiesis; Erythropoietin; Female; Hematopoietic Stem Cell Transplantation; Hemoglobins; Humans; Immunosuppressive Agents; Lenalidomide; Male; Middle Aged; Myelodysplastic Syndromes; Prognosis; Retrospective Studies; Survival Analysis; Young Adult | 2018 |
Outcome of lower-risk myelodysplastic syndrome with ring sideroblasts (MDS-RS) after failure of erythropoiesis- stimulating agents.
Topics: Activin Receptors, Type II; Aged; Anemia, Sideroblastic; Azacitidine; Disease Progression; Erythrocyte Transfusion; Erythropoietin; Female; Ferritins; Follow-Up Studies; Hematinics; Humans; Immunoglobulin Fc Fragments; Kaplan-Meier Estimate; Lenalidomide; Male; Proportional Hazards Models; Recombinant Fusion Proteins; Salvage Therapy; Treatment Failure | 2020 |